Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Division of Cancer Biology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.
Neurochem Res. 2023 Oct;48(10):2936-2968. doi: 10.1007/s11064-023-03955-3. Epub 2023 Jun 6.
Despite ongoing advancements in research, the inability of therapeutics to cross the blood-brain barrier (BBB) makes the treatment of neurological disorders (NDs) a challenging task, offering only partial symptomatic relief. Various adverse effects associated with existing approaches are another significant barrier that prompts the usage of structurally diverse phytochemicals as preventive/therapeutic lead against NDs in preclinical and clinical settings. Despite numerous beneficial properties, phytochemicals suffer from poor pharmacokinetic profile which limits their pharmacological activity and necessitates the utility of nanotechnology for efficient drug delivery. Nanocarriers have been shown to be proficient carriers that can enhance drug delivery, bioavailability, biocompatibility, and stability of phytochemicals. We, thus, conducted a meticulous literature survey using several electronic databases to gather relevant studies in order to provide a comprehensive summary about the use of nanocarriers in delivering phytochemicals as a treatment approach for NDs. Additionally, the review highlights the mechanisms of drug transport of nanocarriers across the BBB and explores their potential future applications in this emerging field.
尽管研究不断取得进展,但治疗药物无法穿过血脑屏障 (BBB),使得治疗神经疾病 (NDs) 成为一项具有挑战性的任务,只能提供部分症状缓解。与现有方法相关的各种不良反应是另一个重要障碍,促使人们在临床前和临床环境中使用结构多样的植物化学物质作为预防/治疗 ND 的先导。尽管具有许多有益特性,但植物化学物质的药代动力学特性较差,限制了它们的药理活性,因此需要纳米技术来有效递送药物。纳米载体已被证明是有效的载体,可增强药物的递送、生物利用度、生物相容性和植物化学物质的稳定性。因此,我们使用了几个电子数据库进行了细致的文献调查,以收集相关研究,从而提供关于纳米载体在递送植物化学物质作为治疗 ND 方法中的使用的全面总结。此外,该综述还强调了纳米载体穿过 BBB 的药物转运机制,并探讨了它们在这一新兴领域的潜在未来应用。